Dksh Holding Ltd · SIX:DKSH
Dksh — Merger or Acquisition (October 2026)
10 slides from Dksh's merger presentation, Oct 19, 2026
Slide 1: DKSH to Acquire NewBridge Pharmaceuticals
DKSH to Acquire NewBridge Pharmaceuticals Establishing a Healthcare Platform in the Middle East and Scaling Up Capabilities October 19, 2026 Delivering Growth – in Asia and Beyond. Page 1
Slide 2: Disclaimer
Disclaimer This presentation is for information purposes only. It does not constitute an offer to sell, or a solicitation of an offer to buy, any securities of DKSH, and it is not a prospectus within the meaning of the Swiss Financial Services Act (FinSA). It does not constitute a recommendation reg
Slide 3: Speakers
Speakers Stefan P. Butz Ido Wallach Patrik Grande Chief Executive Officer Chief Financial Officer Head, Business Unit Healthcare Page 3
Slide 4: Agenda
Agenda 1. Strategic Rationale and Transaction Overview 2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare 3. Financial Impact 4. Key Takeaways 5. Q&A Page 4
Slide 5: Delivering on our Strategy: Accelerating Profitable Growth in Healthcare, in Asia and Beyond
1. Strategic Rationale and Transaction Overview Delivering on our Strategy: Accelerating Profitable Growth in Healthcare, in Asia and Beyond What we said What NewBridge delivers Accelerate more impactful M&A, focused on higher-value A leading platform for specialty and rare disease medicines in busi
Slide 6: NewBridge is a Leading Healthcare Commercialization Platform for Specialty and Rare Disease Medicines
2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare NewBridge is a Leading Healthcare Commercialization Platform for Specialty and Rare Disease Medicines in the Region A Large, Wealthy and Growing Healthcare Market1 ~350 million ~CHF 3 trillion ~2.8x 1.7x USD 6-7 billion People acros
Slide 7: One Integrated Platform to Better Serve our Global Partners
2. Introduction to NewBridge and Strategic Fit with DKSH Healthcare One Integrated Platform to Better Serve our Global Partners NewBridge directly strengthens DKSH Healthcare’s Commercial Outsourcing Platform 1 Scaling up from 17 to 31 markets 2 Specialty, oncology and rare diseases Aligned with DKS
Slide 8: Accretive to Margin and Earnings per Share
3. Financial Impact Accretive to Margin and Earnings per Share Key Figures at a Glance Enterprise value NewBridge Net sales 2027E NewBridge EBITDA margin 2027E USD 390 million ~USD 385 million High single-digit For 100% of NewBridge Expected Net sales in 2027 In the higher-value segment of commercia
Slide 9: Pivotal Step for DKSH Healthcare: Leading Platform, Complementary Fit, Higher-Value Growth, Accretive to EPS
4. Key Takeaways Pivotal Step for DKSH Healthcare: Leading Platform, Complementary Fit, Higher-Value Growth, Accretive to EPS Leading Platform • Leading platform for specialty and rare disease medicines in the region, with long-standing global biopharma with Long-standing partnerships and hard-to-re
Slide 10: Delivering Growth – in Asia and Beyond.
Delivering Growth – in Asia and Beyond. Page 10